New cancer drug enters first human trials
NCT ID NCT06781983
Summary
This is the first study in humans testing a new drug called IPH4502 for patients with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose, check for side effects, and look for early signs that the drug might help control the cancer. The study will enroll about 145 patients who have already tried other treatments without success.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Léon Bérard
RECRUITINGLyon, 69008, France
Contact
-
Gustave Roussy Cancer Institute
RECRUITINGVillejuif, 94805, France
Contact
-
John Theurer Cancer Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
-
Massachusetts General Hospital - Boston
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
-
Mount Sinai Tisch Cancer Center
RECRUITINGNew York, New York, 10029, United States
Contact
-
NEXT Oncology - Dallas
RECRUITINGDallas, Texas, 75039, United States
Contact
-
NEXT Oncology - Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Conditions
Explore the condition pages connected to this study.